Cargando…

Budget Impact Analysis of Expanding Gliflozin Coverage in the CKD Population: A French Perspective

INTRODUCTION: Gliflozins have historically been indicated for type 2 diabetes in France. However, their efficacy has recently been demonstrated in heart failure and chronic kidney disease (CKD), with positive recommendations by Haute Autorité de Santé for gliflozin therapies in these indications. Th...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Pouvourville, Gérard, Rossignol, Patrick, Boussahoua, Meriem, Chevalier, Julie, Gabb, Peter D., Poulnais, Roch, Verboux, Dorian, Rao, Naveen, Sörstadius, Elisabeth, Garcia Sanchez, Juan Jose
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427519/ https://www.ncbi.nlm.nih.gov/pubmed/37341914 http://dx.doi.org/10.1007/s12325-023-02574-2

Ejemplares similares

Gliflozine – in Zukunft Kardioprotektiva?
por: Rauch-Kröhnert, Ursula, et al.
Publicado: (2021)

Selecting Patients at Risk of Developing DKA on Gliflozins
por: Maletkovic, Jelena
Publicado: (2021)

Cardiovascular Benefits from Gliflozins: Effects on Endothelial Function
por: Salvatore, Teresa, et al.
Publicado: (2021)

Gliflozins, Erythropoietin, and Erythrocytosis: Is It Renal Normoxia- or Hypoxia-Driven?
por: Heyman, Samuel N., et al.
Publicado: (2023)

Therapy of Type 2 diabetes: more gliflozines and less metformin?
por: Verdecchia, Paolo, et al.
Publicado: (2023)

Surprises in cardiology: efficacy of gliflozines in heart failure even in the absence of diabetes
por: Bragagni, Alessio, et al.
Publicado: (2021)

Evolution of health care utilization and expenditure during the year before death in 2015 among people with cancer: French snds-based cohort study
por: Tanguy-Melac, Audrey, et al.
Publicado: (2021)

A French Value Set for the EQ-5D-5L
por: Andrade, Luiz Flavio, et al.
Publicado: (2020)

SAVOR-TIMI to DECLARE-TIMI: A Review on Cardiovascular Outcome Trials of Incretin-modulators and Gliflozins
por: Singh, Awadhesh K., et al.
Publicado: (2019)

Gliflozins for the prevention of stroke in diabetes and cardiorenal diseases: A meta-analysis of cardiovascular outcome trials
por: Zhao, Li-Min, et al.
Publicado: (2021)

State budget transfers to Health Insurance to expand coverage to people outside formal sector work in Latin America
por: Mathauer, Inke, et al.
Publicado: (2017)

Meta-analyzing the factors affecting the efficacy of gliflozins in patients with heart failure based on heart failure trials
por: Yin, Daogen, et al.
Publicado: (2021)

Rationale and design of the Biventricular Evaluation of Gliflozins effects In chroNic Heart Failure: BEGIN‐HF study
por: Correale, Michele, et al.
Publicado: (2023)

Metabolism and Chemical Degradation of New Antidiabetic Drugs: A Review of Analytical Approaches for Analysis of Glutides and Gliflozins
por: Gumieniczek, Anna, et al.
Publicado: (2023)

Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study
por: Patorno, Elisabetta, et al.
Publicado: (2018)

Possible Preventative/Rehabilitative Role of Gliflozins in OSA and T2DM. A Systematic Literature Review-Based Hypothesis
por: Monda, Vincenzo Maria, et al.
Publicado: (2021)

Gliflozins Have an Anti-Inflammatory Effect on Renal Proximal Tubular Epithelial Cells in a Diabetic and Inflammatory Microenvironment In Vitro
por: Koch, Benjamin, et al.
Publicado: (2023)

Gliflozins: From Antidiabetic Drugs to Cornerstone in Heart Failure Therapy—A Boost to Their Utilization and Multidisciplinary Approach in the Management of Heart Failure
por: Pistelli, Lorenzo, et al.
Publicado: (2023)

Effectiveness of Montelukast on asthma control in infants: methodology of a French claims data study
por: Belhassen, Manon, et al.
Publicado: (2015)

Changes in Prevalence and Health Checkup Coverage Rate of Chronic Kidney Disease (CKD) after Introduction of Prefecture-Wide CKD Initiative: Results of the Kagawa Association of CKD Initiatives
por: Sofue, Tadashi, et al.
Publicado: (2021)

Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle‐stimulated endothelial senescence and dysfunction: protective effect of gliflozins
por: Park, Sin-Hee, et al.
Publicado: (2021)

Sodium-Glucose Co-transporter 2 Inhibitors/Gliflozins: A New Miracle Therapy for Heart Failure Patients Irrespective of Diabetes Status?
por: Ehsan, Paghunda, et al.
Publicado: (2022)

Sodium–Glucose Cotransporter 2 Inhibitors in Patients with Diabetes and Coronary Artery Disease: Translating the Benefits of the Molecular Mechanisms of Gliflozins into Clinical Practice
por: Cesaro, Arturo, et al.
Publicado: (2023)

Short-term anti-remodeling effects of gliflozins in diabetic patients with heart failure and reduced ejection fraction: an explainable artificial intelligence approach
por: Mele, Marco, et al.
Publicado: (2023)

Coverage-Balancing User Selection in Mobile Crowd Sensing with Budget Constraint
por: Wang, Yanan, et al.
Publicado: (2019)

Budgeting challenges on the path towards universal health coverage: the case of Benin
por: Paul, Elisabeth, et al.
Publicado: (2020)

Is expanding Medicare coverage cost-effective?
por: Franks, Peter, et al.
Publicado: (2005)

Recent advances in expanding the coverage of the lipidome
por: Tumanov, Sergey, et al.
Publicado: (2017)

Budgeting for comprehensive sexual and reproductive health and rights under universal health coverage
por: Lince-Deroche, Naomi, et al.
Publicado: (2020)

Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations
por: Yau, Kevin, et al.
Publicado: (2022)

Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations
por: Yau, Kevin, et al.
Publicado: (2022)

A comparative public health and budget impact analysis of pneumococcal vaccines: The French case
por: Jiang, Yiling, et al.
Publicado: (2015)

Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France
por: Cotté, François-Emery, et al.
Publicado: (2011)

Expanding health care coverage for the uninsured in Texas.
Publicado: (2001)

The French Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) cohort study
por: Stengel, Bénédicte, et al.
Publicado: (2014)

From Universal Health Coverage services packages to budget appropriation: the long journey to implementation
por: Soucat, Agnès, et al.
Publicado: (2023)

Introduction: expanding concepts of chronic kidney disease-mineral and bone disorder (CKD-MBD)
por: Fukagawa, Masafumi, et al.
Publicado: (2013)

CAKUT: A Pediatric and Evolutionary Perspective on the Leading Cause of CKD in Childhood
por: Chevalier, Robert L.
Publicado: (2023)

Dictionary of science and technology, English-French
por: Dorian, Angelo Francis
Publicado: (1979)

Budgeting for a billion: applying health technology assessment (HTA) for universal health coverage in India
por: Dabak, Saudamini Vishwanath, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qcbf8p974p9tci8r5r4ujquqqv